Abstract
® ) is an oral multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and other solid tumors including metastatic differentiated thyroid cancer, at a starting dose of 400 mg twice daily (1-4). The most common adverse effects are fatigue, diarrhea, and various other dermatologic side effects (1). Recently, a meta-analysis of dermatological toxicities associated with sorafenib has been published, (5) and a hand-foot-skin reactions (HFSR) was most often found, but also rash/desquamation, alopecia, pruritus and dry skin. Nail involvement has been reported, in particular sub-ungual splinter hemorrhages (6). We describe a patient with longitudinal melanonychia and blue lunulae that developed during sorafenib therapy of metastatic thyroid carcinoma.
Highlights
Molecular targeted therapy with monoclonal antibodies and low molecular weight inhibitors have gained increasing importance in the treatment of malignant tumors
A meta-analysis of dermatological toxicities associated with sorafenib has been published, [5] and a hand-foot-skin reactions (HFSR) was most often found, and rash/desquamation, alopecia, pruritus and dry skin
We describe a patient with longitudinal melanonychia and blue lunulae that developed during sorafenib therapy of metastatic thyroid carcinoma
Summary
Molecular targeted therapy with monoclonal antibodies and low molecular weight inhibitors have gained increasing importance in the treatment of malignant tumors. Sorafenib (Nexavar®) is an oral multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and other solid tumors including metastatic differentiated thyroid cancer, at a starting dose of 400 mg twice daily [1,2,3,4]. The most common adverse effects are fatigue, diarrhea, and various other dermatologic side effects [1]. A meta-analysis of dermatological toxicities associated with sorafenib has been published, [5] and a hand-foot-skin reactions (HFSR) was most often found, and rash/desquamation, alopecia, pruritus and dry skin. We describe a patient with longitudinal melanonychia and blue lunulae that developed during sorafenib therapy of metastatic thyroid carcinoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
